<DOC>
	<DOCNO>NCT02762513</DOCNO>
	<brief_summary>This study prospective , single-institution , single-arm phase II study Axitinib patient unresectable recurrent metastatic head neck squamous cell carcinoma . The subject start treatment 5 mg Axitinib twice day continuously , subsequent dose escalation 7 mg 10 mg twice day absence grade 2 bad toxicity . This follow clinical and/or radiologic response assessment 8 week subsequently every 2 month disease progression intolerable toxicity .</brief_summary>
	<brief_title>Expansion Trial Axitinib In Head And Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically document squamous cell head neck cancer without metastasis , amenable curative treatment ; patient document refusal curative treatment . Presence measurable disease CT scan . Adequate bone marrow , hepatic , renal function Age ≥18 year . ECOG ( Eastern Cooperative Oncology Group score system use quantify general wellbeing activity daily life ; score range 0 5 0 represent perfect health 5 represent death . ) performance status 02 . Life expectancy ≥12 week . No evidence preexist uncontrolled hypertension document 2 baseline blood pressure read take least 30 minute apart . Patients whose hypertension control antihypertensive therapy eligible . Women childbearing potential must negative serum urine pregnancy test within 3 day prior treatment . Signed date informed consent Willingness ability comply schedule visit , treatment plan , include willingness take Axitinib , laboratory test , study procedure . If curative treatment option form chemoradiation exist patient unresectable disease , attempt first must fail , unless patient document refusal curative treatment . Central lung lesion involve major blood vessel ( artery vein ) tumor encase major blood vessel ( i.e . carotid artery ) . History hemoptysis Gastrointestinal abnormality cause impaired absorption require intravenous alimentation , prior surgical procedure affect absorption include gastric resection , treatment active peptic ulcer disease past 6 month , active gastrointestinal bleeding , unrelated cancer , evidence hematemesis , hematochezia melena past 3 month without evidence resolution document endoscopy colonoscopy , malabsorption syndrome . Previous treatment antiangiogenesis agent include thalidomide , inhibitor epidermal growth factor ( EGF ) , platelet derive growth factor ( PDGF ) , fibroblast growth factor ( FGF ) receptor within 30 day precede study entrance . Current use anticipate inability avoid use drug know potent CYP3A4/5 inhibitor Current use anticipate inability avoid use drug know CYP3A4/5 inducer Active seizure disorder evidence untreated progressive brain metastasis , spinal cord compression , carcinomatous meningitis ( Subjects brain metastasis eligible treated CT MRI evidence least 4 week CNS ( Central Nervous System ) metastasis treatment complete. ) . A serious uncontrolled medical disorder active infection would impair ability receive study treatment . History malignancy ( head neck cancer ) except treat curative intent skin cancer ( melanoma ) , situ breast situ cervical cancer , treat curative intent cancer evidence disease 2 year . Major surgery &lt; 4 week radiation therapy &lt; 2 week start study treatment . Prior palliative radiotherapy metastatic lesion ( ) permit , provide least one measurable lesion irradiate . Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol . Patients ( male female ) procreative potential willing able use adequate contraception practice abstinence Women pregnant breastfeeding . Patients history bleed diathesis , arterial thromboembolism , current use therapeutic anticoagulation oral vitamin K antagonist , factor Xa inhibitor , heparin product , oral direct thrombin inhibitor , presence nonhealing wound . Lowdose anticoagulant maintenance patency central venous access device prevention deep venous thrombosis allow . Patients reside prison . Prior experimental therapy within 30 day plan start trial . HIV virus infection irrespective viral load , treatment status , CD4 count , acquire immunodeficiency syndrome ( AIDS ) relate illness . HIV test require protocol . Any follow within 12 month prior study drug administration : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack . History deep vein thrombosis pulmonary embolism within 6 month anticipate start Axitinib . Availability curative treatment option patient 's cancer , whether surgery , chemotherapy , radiation , combination thereof , unless patient document refusal curative treatment . Increased risk wound dehiscence presence nonhealing wound .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>